Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma

Douglas R. Kennedy, Brian J. Hartnett, Jeffrey S. Kennedy, William Vernau, Peter F Moore, Thomas O'Malley, Linda C. Burkly, Paula S. Henthorn, Peter J. Felsburg

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have previously shown that in vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency (XSCID) results in sustained T cell reconstitution and sustained marking in myeloid and B cells for up to 4 years with no evidence of any serious adverse effects. The purpose of this study was to determine whether ex vivo γ-retroviral gene therapy of XSCID dogs results in a similar outcome. Eight of 12 XSCID dogs treated with an average of dose of 5.8×106 transduced CD34+ cells/kg successfully engrafted producing normal numbers of gene-corrected CD45RA+ (naïve) T cells. However, this was followed by a steady decrease in CD45RA+ T cells, T cell diversity, and thymic output as measured by T cell receptor excision circles (TRECs) resulting in a T cell lymphopenia. None of the dogs survived past 11 months post treatment. At necropsy, few gene-corrected thymocytes were observed correlating with the TREC levels and one of the dogs was diagnosed with a thymic T cell lymphoma that was attributed to the gene therapy. This study highlights the outcome differences between the ex vivo and in vivo approach to γ-retroviral gene therapy and is the first to document a serious adverse event following gene therapy in a canine model of a human genetic disease.

Original languageEnglish (US)
Pages (from-to)36-48
Number of pages13
JournalVeterinary Immunology and Immunopathology
Volume142
Issue number1-2
DOIs
StatePublished - Jul 15 2011

Fingerprint

X-Linked Combined Immunodeficiency Diseases
severe combined immunodeficiency
therapy dogs
gene therapy
T-Cell Lymphoma
lymphoma
Genetic Therapy
T-lymphocytes
Dogs
T-Lymphocytes
T-Cell Antigen Receptor
dogs
Inborn Genetic Diseases
Lymphopenia
Medical Genetics
Myeloid Cells
Thymocytes
Genes
Canidae
B-Lymphocytes

Keywords

  • Canine
  • Gene therapy
  • X-linked severe combined immunodeficiency

ASJC Scopus subject areas

  • Immunology
  • veterinary(all)

Cite this

Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma. / Kennedy, Douglas R.; Hartnett, Brian J.; Kennedy, Jeffrey S.; Vernau, William; Moore, Peter F; O'Malley, Thomas; Burkly, Linda C.; Henthorn, Paula S.; Felsburg, Peter J.

In: Veterinary Immunology and Immunopathology, Vol. 142, No. 1-2, 15.07.2011, p. 36-48.

Research output: Contribution to journalArticle

Kennedy, Douglas R. ; Hartnett, Brian J. ; Kennedy, Jeffrey S. ; Vernau, William ; Moore, Peter F ; O'Malley, Thomas ; Burkly, Linda C. ; Henthorn, Paula S. ; Felsburg, Peter J. / Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma. In: Veterinary Immunology and Immunopathology. 2011 ; Vol. 142, No. 1-2. pp. 36-48.
@article{dbb58d44df404c249b4aa3f10c9b6df3,
title = "Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma",
abstract = "We have previously shown that in vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency (XSCID) results in sustained T cell reconstitution and sustained marking in myeloid and B cells for up to 4 years with no evidence of any serious adverse effects. The purpose of this study was to determine whether ex vivo γ-retroviral gene therapy of XSCID dogs results in a similar outcome. Eight of 12 XSCID dogs treated with an average of dose of 5.8×106 transduced CD34+ cells/kg successfully engrafted producing normal numbers of gene-corrected CD45RA+ (na{\"i}ve) T cells. However, this was followed by a steady decrease in CD45RA+ T cells, T cell diversity, and thymic output as measured by T cell receptor excision circles (TRECs) resulting in a T cell lymphopenia. None of the dogs survived past 11 months post treatment. At necropsy, few gene-corrected thymocytes were observed correlating with the TREC levels and one of the dogs was diagnosed with a thymic T cell lymphoma that was attributed to the gene therapy. This study highlights the outcome differences between the ex vivo and in vivo approach to γ-retroviral gene therapy and is the first to document a serious adverse event following gene therapy in a canine model of a human genetic disease.",
keywords = "Canine, Gene therapy, X-linked severe combined immunodeficiency",
author = "Kennedy, {Douglas R.} and Hartnett, {Brian J.} and Kennedy, {Jeffrey S.} and William Vernau and Moore, {Peter F} and Thomas O'Malley and Burkly, {Linda C.} and Henthorn, {Paula S.} and Felsburg, {Peter J.}",
year = "2011",
month = "7",
day = "15",
doi = "10.1016/j.vetimm.2011.04.003",
language = "English (US)",
volume = "142",
pages = "36--48",
journal = "Veterinary Immunology and Immunopathology",
issn = "0165-2427",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma

AU - Kennedy, Douglas R.

AU - Hartnett, Brian J.

AU - Kennedy, Jeffrey S.

AU - Vernau, William

AU - Moore, Peter F

AU - O'Malley, Thomas

AU - Burkly, Linda C.

AU - Henthorn, Paula S.

AU - Felsburg, Peter J.

PY - 2011/7/15

Y1 - 2011/7/15

N2 - We have previously shown that in vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency (XSCID) results in sustained T cell reconstitution and sustained marking in myeloid and B cells for up to 4 years with no evidence of any serious adverse effects. The purpose of this study was to determine whether ex vivo γ-retroviral gene therapy of XSCID dogs results in a similar outcome. Eight of 12 XSCID dogs treated with an average of dose of 5.8×106 transduced CD34+ cells/kg successfully engrafted producing normal numbers of gene-corrected CD45RA+ (naïve) T cells. However, this was followed by a steady decrease in CD45RA+ T cells, T cell diversity, and thymic output as measured by T cell receptor excision circles (TRECs) resulting in a T cell lymphopenia. None of the dogs survived past 11 months post treatment. At necropsy, few gene-corrected thymocytes were observed correlating with the TREC levels and one of the dogs was diagnosed with a thymic T cell lymphoma that was attributed to the gene therapy. This study highlights the outcome differences between the ex vivo and in vivo approach to γ-retroviral gene therapy and is the first to document a serious adverse event following gene therapy in a canine model of a human genetic disease.

AB - We have previously shown that in vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency (XSCID) results in sustained T cell reconstitution and sustained marking in myeloid and B cells for up to 4 years with no evidence of any serious adverse effects. The purpose of this study was to determine whether ex vivo γ-retroviral gene therapy of XSCID dogs results in a similar outcome. Eight of 12 XSCID dogs treated with an average of dose of 5.8×106 transduced CD34+ cells/kg successfully engrafted producing normal numbers of gene-corrected CD45RA+ (naïve) T cells. However, this was followed by a steady decrease in CD45RA+ T cells, T cell diversity, and thymic output as measured by T cell receptor excision circles (TRECs) resulting in a T cell lymphopenia. None of the dogs survived past 11 months post treatment. At necropsy, few gene-corrected thymocytes were observed correlating with the TREC levels and one of the dogs was diagnosed with a thymic T cell lymphoma that was attributed to the gene therapy. This study highlights the outcome differences between the ex vivo and in vivo approach to γ-retroviral gene therapy and is the first to document a serious adverse event following gene therapy in a canine model of a human genetic disease.

KW - Canine

KW - Gene therapy

KW - X-linked severe combined immunodeficiency

UR - http://www.scopus.com/inward/record.url?scp=79957931892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957931892&partnerID=8YFLogxK

U2 - 10.1016/j.vetimm.2011.04.003

DO - 10.1016/j.vetimm.2011.04.003

M3 - Article

VL - 142

SP - 36

EP - 48

JO - Veterinary Immunology and Immunopathology

JF - Veterinary Immunology and Immunopathology

SN - 0165-2427

IS - 1-2

ER -